Zacks Investment Research upgraded shares of ANACOR PHARMACT (ANAC) from UNDERPERFORM to NEUTRAL on July 08, 2014, with a target price of $17.20.
Anacor Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovery, development and commercialization of novel small-molecule therapeutics derived from its boron chemistry platform. Its three lead product candidates include two topically administered dermatologic compounds-AN2690, an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory for the treatment of psoriasis, as well as a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria-GSK2251052. Additionally, the Company also develops topical antifungal product for the treatment of onychomycosis and skin fungal infections, topical anti-inflammatory product for the treatment of psoriasis and atopic dermatitis. Anacor Pharmaceuticals, Inc. is headquartered in Palo Alto, California.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ANACOR PHARMACT (ANAC),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment